Skip to content

effects of Probiotic Bacteria on Gastrointestinal Side Effects of the Radioiodine Therapy in Patients with Differentiated Thyroid Carcinoma

Does Oral Intake of Probiotic Bacteria Mitigate the Gastrointestinal Side Effects of the Radioiodine Therapy in Patients with Differentiated Thyroid Carcinoma?

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220226054126N1
Enrollment
40
Registered
2022-04-18
Start date
2022-04-09
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduction of gastrointestinal complications due to iodine therapy of differentiated thyroid cancer. Malignant neoplasm of thyroid gland

Interventions

Intervention 1: Intervention group: A group of patients who, according to the standard protocol, in addition to radioactive iodine therapy with an activity of 5550 MB from one day before the start of

Sponsors

Shiraz university of medical science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with Differentiated Thyroid Carcinoma under Radioiodine Therapy Patients between 18-90 years old

Exclusion criteria

Exclusion criteria: Consumption of narcotic painkillers Acute or chronic complications before starting treatment Take any antibiotics from one week before the start of treatment until the end of the study Use of any prebiotics and probiotics in 15 days before starting treatment Use of anti-diarrheal drugs (unless prescribed by a doctor) History of treatment with radioactive iodine or radiation therapy in previous years Patient dissatisfaction Lack of adherence to diet

Design outcomes

Primary

MeasureTime frame
Gastrointestinal complications. Timepoint: At the beginning of the study and one month after starting bacterial probiotics. Method of measurement: Question from the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammadjavad Mortazavi

Shiraz University of Medical Sciences

mortazavismj@gmail.com+98 71 3230 5410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026